111.45
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt A?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$111.63
Offen:
$113.17
24-Stunden-Volumen:
1.06M
Relative Volume:
0.49
Marktkapitalisierung:
$31.50B
Einnahmen:
$7.07B
Nettoeinkommen (Verlust:
$1.29B
KGV:
24.57
EPS:
4.5355
Netto-Cashflow:
$993.00M
1W Leistung:
-3.04%
1M Leistung:
-11.31%
6M Leistung:
-9.47%
1J Leistung:
-4.90%
Agilent Technologies Inc Stock (A) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
(408) 345-8886
Adresse
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies Inc
|
111.45 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
TMO
Thermo Fisher Scientific Inc
|
466.31 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
186.84 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
572.75 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
WAT
Waters Corp
|
285.83 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-17 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | Citigroup | Neutral |
| 2023-05-24 | Bestätigt | Credit Suisse | Outperform |
| 2023-05-24 | Bestätigt | Evercore ISI | Outperform |
| 2023-05-24 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Bestätigt | Robert W. Baird | Outperform |
| 2023-05-24 | Bestätigt | SVB Securities | Outperform |
| 2023-05-24 | Bestätigt | Stifel | Hold |
| 2023-05-24 | Bestätigt | TD Cowen | Outperform |
| 2023-05-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-05-11 | Eingeleitet | Barclays | Equal Weight |
| 2023-01-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-07-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Bestätigt | BofA Securities | Buy |
| 2022-02-23 | Bestätigt | Citigroup | Buy |
| 2022-02-23 | Bestätigt | Cowen | Outperform |
| 2022-02-23 | Bestätigt | Evercore ISI | Outperform |
| 2022-02-23 | Bestätigt | Stifel | Hold |
| 2022-02-23 | Bestätigt | Wells Fargo | Overweight |
| 2021-11-23 | Bestätigt | BofA Securities | Buy |
| 2021-11-23 | Bestätigt | Cowen | Outperform |
| 2021-11-23 | Bestätigt | Stifel | Hold |
| 2021-03-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Hochstufung | UBS | Neutral → Buy |
| 2020-11-17 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Neutral |
| 2020-08-19 | Bestätigt | BofA Securities | Neutral |
| 2020-08-19 | Bestätigt | Citigroup | Neutral |
| 2020-08-19 | Bestätigt | Jefferies | Buy |
| 2020-08-19 | Bestätigt | Robert W. Baird | Outperform |
| 2020-08-19 | Bestätigt | SVB Leerink | Outperform |
| 2020-08-19 | Bestätigt | Stifel | Hold |
| 2020-08-19 | Bestätigt | Wells Fargo | Overweight |
| 2020-02-24 | Herabstufung | Needham | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-26 | Bestätigt | Needham | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | UBS | Buy → Neutral |
| 2019-07-16 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Herabstufung | Barclays | Overweight → Equal Weight |
Alle ansehen
Agilent Technologies Inc Aktie (A) Neueste Nachrichten
Magnetar Financial LLC Decreases Holdings in Agilent Technologies, Inc. $A - MarketBeat
Schroder Investment Management Group Buys 75,796 Shares of Agilent Technologies, Inc. $A - MarketBeat
Agilent Technologies, Inc. $A Shares Purchased by Natixis Advisors LLC - MarketBeat
Preventive Control Of Sequencing Through The Insert With The Agilent 5200 Fragment Analyzer System - bioprocessonline.com
Agilent Expands CDMO Role With Advanced Therapeutics As Shares Lag Targets - simplywall.st
Agilent Technologies, Inc. (A) price target cut to $155 at Baird - MSN
Vestcor Inc Sells 10,204 Shares of Agilent Technologies, Inc. $A - MarketBeat
Mackenzie Financial Corp Buys 324,461 Shares of Agilent Technologies, Inc. $A - MarketBeat
Agilent unifies CDMO capabilities across Canada and United States - BioSpectrum India
Legal & General Group Plc Raises Position in Agilent Technologies, Inc. $A - MarketBeat
Korea Investment CORP Has $12.95 Million Stake in Agilent Technologies, Inc. $A - MarketBeat
Agilent launches unified CDMO business combining US, Canada units - Investing.com India
Blair William & Co. IL Decreases Holdings in Agilent Technologies, Inc. $A - MarketBeat
Lab chromatographs are quietly getting an AI upgrade in the US - AD HOC NEWS
Agilent Launches Advanced Therapeutics CDMO Solution for US and Canada - Contract Pharma
Agilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets - simplywall.st
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States - BioSpace
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More - AOL.com
Agilent Technologies, Inc. $A Shares Sold by Swiss National Bank - MarketBeat
Agilent launches unified CDMO division across Canada and United States - StreetInsider
Lab Chromatographs Are Quietly Getting Smarter. Here Is Why It Matters - AD HOC NEWS
Jim Cramer on Agilent Technologies: “I Don’t Think You Need It” - Yahoo Finance UK
Agilent Technologies, Inc. $A Shares Sold by Russell Investments Group Ltd. - MarketBeat
Agilent Bets On Pathology Innovation With Biocare Acquisition - Yahoo Finance
Agilent snaps up pathology firm Biocare Medical for $950 million - malaysiasun.com
Is Agilent Technologies Stock Underperforming the S&P 500? - Barchart.com
Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy - CHEManager
Van ECK Associates Corp Sells 10,815 Shares of Agilent Technologies, Inc. $A - MarketBeat
Ceredex Value Advisors LLC Makes New $24.39 Million Investment in Agilent Technologies, Inc. $A - MarketBeat
Why Agilent Technologies Just Paid $950 Million For Biocare Medical (NYSE:A) - Seeking Alpha
First Trust Advisors LP Increases Stock Position in Agilent Technologies, Inc. $A - MarketBeat
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
Bank of America Maintains Neutral on Agilent Technologies (A) March 2026 - Meyka
Agilent to buy Biocare Medical from Excellere and GHO Capital - pehub.com
Agilent Technologies: $950 Million Acquisition Of Pathology Diagnostics Company Biocare Medical - Pulse 2.0
Agilent Technologies to acquire Biocare Medical for $950 million - The American Bazaar
Agilent Technologies to Acquire Biocare Medical in $950 Million Deal - Clinical Lab Products
Why Agilent Stock Is Slipping Premarket Today - Stocktwits
Agilent to Acquire Biocare Medical in $950 Million All-Cash Deal - TradingView
Sullivan & Cromwell Advises Agilent On $950M Biocare Buy - Law360
Agilent to buy Biocare Medical for $950M - Healthcare Dive
Agilent Technologies to acquire Biocare Medical in $950m deal - Medical Device Network
Agilent buys Biocare for $950M - BioWorld MedTech
BofA reiterates Agilent stock rating on Biocare acquisition - Investing.com
Agilent stock rises on $950M Biocare Medical acquisition - Investing.com South Africa
Agilent expands pathology portfolio with acquisition of Biocare Medical for $950 M - BioSpectrum India
Agilent to acquire Biocare Medical in $950 million all-cash deal - PharmaLive
Sienna Gestion Sells 26,245 Shares of Agilent Technologies, Inc. $A - MarketBeat
Victory Capital Management Inc. Boosts Stake in Agilent Technologies, Inc. $A - MarketBeat
Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip - Investing.com
Agilent to acquire Biocare Medical for $950M, expanding pathology portfolio - MSN
Finanzdaten der Agilent Technologies Inc-Aktie (A)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):